EFFICACY OF TELAPREVIR DOSED TWICE DAILY VERSUS EVERY 8 HOURS BY IL28B GENOTYPE: RESULTS FROM THE PHASE III OPTIMIZE STUDY

被引：4
|
作者：
Buti, M. [1 ,2 ]
Agarwal, K. [3 ]
Horsmans, Y. [4 ]
Sievert, W. [5 ,6 ]
Janczewska, E. [7 ]
Zeuzem, S. [8 ]
Nyberg, L. [9 ]
Brown, R. S., Jr. [10 ]
Hezode, C. [11 ]
Rizzetto, M. [12 ]
Parana, R. [13 ]
De Meyer, S. [14 ]
DeMasi, R. [15 ]
Luo, D. [15 ]
Witek, J. [15 ]
机构：
[1] Hosp Gen Valle Hebron, Barcelona, Spain
[2] Ciberehd, Inst Carlos 3, Barcelona, Spain
[3] Kings Coll Hosp London, London, England
[4] Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium
[5] Monash Med Ctr, Melbourne, Vic, Australia
[6] Monash Univ, Melbourne, Vic 3004, Australia
[7] Outpatients Clin Hepatol, Myslowice, Poland
[8] Goethe Univ Frankfurt, Med Ctr, D-60054 Frankfurt, Germany
[9] Kaiser Permanente, San Diego, CA USA
[10] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA
[11] Hop Henri Mondor, F-94010 Creteil, France
[12] Univ Turin, Turin, Italy
[13] Univ Fed Bahia, Sch Med, BR-41170290 Salvador, BA, Brazil
[14] Janssen Infect Dis BVBA, Beerse, Belgium
[15] Janssen Res & Dev LLC, Titusville, NJ USA
来源：
JOURNAL OF HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
10.1016/S0168-8278(13)60800-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
798
引用
收藏
页码：S326 / S326
页数：1
相关论文
共 13 条
  • [1] ANEMIA AND ITS MANAGEMENT IN PATIENTS TREATED WITH TELAPREVIR TWICE DAILY VERSUS EVERY 8 HOURS IN THE PHASE III OPTIMIZE STUDY
    Zeuzem, S.
    Buti, M.
    Agarwal, K.
    Horsmans, Y.
    Sievert, W.
    Janczewska, E.
    Nyberg, L.
    Brown, R. S., Jr.
    Hezode, C.
    Rizzetto, M.
    Parana, R.
    De Meyer, S.
    De Masi, R.
    Luo, D.
    Van Solingen-Ristea, R.
    Witek, J.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S379 - S379
  • [2] FACTORS INFLUENCING RENAL FUNCTION IN PATIENTS RECEIVING TELAPREVIR TWICE DAILY OR EVERY 8 HOURS: RESULTS FROM THE PHASE III OPTIMIZE STUDY
    Buti, M.
    Agarwal, K.
    Horsmans, Y.
    Sievert, W.
    Janczewska, E.
    Zeuzem, S.
    Nyberg, L.
    Brown, R. S., Jr.
    Hezode, C.
    Rizzetto, M.
    Parana, R.
    De Meyer, S.
    Demasi, R.
    Luo, D.
    Bertelsen, K.
    Witek, J.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S491 - S491
  • [3] Incidence of virological failure and emergence of resistance with twice daily versus every 8 h administration of telaprevir in the OPTIMIZE study
    Dierynck, I.
    Ghys, A.
    Witek, J.
    Luo, D.
    Janssen, K.
    Daems, B.
    Picchio, G.
    Buti, M.
    De Meyer, S.
    ANTIVIRAL THERAPY, 2013, 18 : A52 - A52
  • [4] OPTIMIZE trial: Non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naive, genotype 1 HCV infected patients
    Buti, Maria
    Agarwal, Kosh
    Horsmans, Yves J.
    Sievert, William
    Janczewska, Ewa
    Zeuzem, Stefan
    Nyberg, Lisa
    Brown, Robert S.
    Hezode, Christophe
    Rizzetto, Mario
    Parana, Raymundo
    De Meyer, Sandra
    Luo, Donghan
    Witek, James
    HEPATOLOGY, 2012, 56 (06) : 1521 - 1522
  • [5] OPTIMIZE trial: Non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naive, genotype 1 HCV infected patients
    Maieron, Andreas
    Buti, Maria
    Agarwal, Kosh
    Horsmans, Yves J.
    Sievert, William
    Janczewska, Ewa
    Zeuzem, Stefan
    Nyberg, Lisa
    Brown, Robert S.
    Hezode, Christophe
    Rizzetto, Mario
    Parana, Raymundo
    De Meyer, Sandra
    Luo, Donghan
    Witek, James
    SWISS MEDICAL WEEKLY, 2013, 143 : 4S - 4S
  • [6] OPTIMIZE trial: Non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naive, genotype 1 HCV infected patients
    Sievert, W.
    Buti, M.
    Agarwal, K.
    Horsmans, Y.
    Janczewska, E.
    Zeuzem, S.
    Nyberg, L.
    Brown, R. S., Jr.
    Hezode, C.
    Rizzetto, M.
    Parana, R.
    De Meyer, S.
    Luo, D.
    Witek, J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 166 - 166
  • [7] Pre-treatment IP-10 levels and IL28B genotype as predictive markers for SVR in treatment-naive patients with genotype 1 HCV infection treated with telaprevir/peginterferon/ribavirin in the OPTIMIZE study
    Vijgen, Leen
    Dierynck, Inge
    Janssen, Katrien
    Talloen, Willem
    Gys, Luc
    Vanhoof, Greet
    Luo, Donghan
    De Meyer, Sandra
    Witek, James
    Aerssens, Jeroen
    HEPATOLOGY, 2013, 58 : 1096A - 1097A
  • [8] Multicenter Prospective Study to Evaluate the Efficacy of Triple Therapy with Telaprevir in Patients with Genotype 1b HCV According to the Algorithm Based on Drug Adherence and IL28B Gene as Well as Response-Guided Therapy: the AG & RGT Trial
    Sugawara, Kayoko
    Inao, Mie
    Nakayama, Nobuaki
    Mochida, Satoshi
    HEPATOLOGY, 2013, 58 : 1122A - 1123A
  • [9] ADHERENCE WITH TELAPREVIR BID vs. q8h DOSING IN TREATMENT-NAIVE HCV-INFECTED PATIENTS: RESULTS FROM THE PHASE III OPTIMIZE STUDY
    Sievert, W.
    Buti, M.
    Agarwal, K.
    Horsmans, Y.
    Zeuzem, S.
    Janczewska, E.
    Nyberg, L.
    Brown, R. S., Jr.
    Hezode, C.
    Rizzetto, M.
    Parana, R.
    De Meyer, S.
    De Masi, R.
    Luo, D.
    Witek, J.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S373 - S373
  • [10] rs12979860 IL28B GENOTYPE IS ASSOCIATED WITH ADVANCED FIBROSIS IN HCV GENOTYPE 1-INFECTED EUROPEAN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS FROM THE INTERNATIONAL GEN-C STUDY
    Mangia, A.
    De Ledinghen, V.
    Bailly, F.
    Brahm, J.
    Keiss, J.
    Valantinas, J.
    Rasmann, N.
    Riachi, G.
    Messinger, D.
    Caputo, A.
    Foster, G. R.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S473 - S473
12